BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30827508)

  • 21. Glypican-3-specific cytotoxic T lymphocytes induced by human leucocyte antigen-A*0201-restricted peptide effectively kill hepatocellular carcinoma cells in vitro.
    Zeng JZ; Liu Y; Huang F; He ZH; Sun H; Lu YD; Lei JH; Luo RC
    Asian Pac J Trop Med; 2017 Nov; 10(11):1084-1089. PubMed ID: 29203107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
    Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
    Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
    Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
    Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
    Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.
    Liu Q; Yang Y; Tan X; Tao Z; Adah D; Yu S; Lu J; Zhao S; Qin L; Qin L; Chen X
    Oncotarget; 2017 Apr; 8(15):24785-24796. PubMed ID: 28445973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
    Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
    Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human induced pluripotent stem cell-derived lung progenitor and alveolar epithelial cells attenuate hyperoxia-induced lung injury.
    Shafa M; Ionescu LI; Vadivel A; Collins JJP; Xu L; Zhong S; Kang M; de Caen G; Daneshmand M; Shi J; Fu KZ; Qi A; Wang Y; Ellis J; Stanford WL; Thébaud B
    Cytotherapy; 2018 Jan; 20(1):108-125. PubMed ID: 29056548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
    Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
    Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
    Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells.
    Haruta M; Tomita Y; Yuno A; Matsumura K; Ikeda T; Takamatsu K; Haga E; Koba C; Nishimura Y; Senju S
    Gene Ther; 2013 May; 20(5):504-13. PubMed ID: 22875043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
    Bae J; Martinson JA; Klingemann HG
    Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of Tumor Antigen-Specific Cytotoxic T Lymphocytes from Pluripotent Stem Cells.
    Chen X; Lei F; Wang L; Xiong X; Song J
    Methods Mol Biol; 2019; 1884():43-55. PubMed ID: 30465194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.